The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Apricot-l: Results of a biomarker-based phase II randomized placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) patients.
B. J. Gitlitz
No relevant relationships to disclose
E. D. Bernstein
No relevant relationships to disclose
G. P. Keogh
No relevant relationships to disclose
E. S. Santos
No relevant relationships to disclose
G. A. Otterson
Consultant or Advisory Role - Celgene; Genentech
Research Funding - Celgene; Genentech; Pfizer
G. Milne
Research Funding - Tragara Pharmaceuticals
M. Syto
Employment or Leadership Position - Tragara Pharmaceuticals
Stock Ownership - Tragara Pharmaceuticals
S. L. Zaknoen
Employment or Leadership Position - Tragara Pharmaceuticals
Stock Ownership - Tragara Pharmaceuticals